MGX
HEALTHCAREMetagenomi Inc
$1.43+0.02 (+1.42%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MGX Today?
No stock-specific AI insight has been generated for MGX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.25$3.95
$1.43
Fundamentals
Market Cap$53M
P/E Ratio—
EPS$-2.36
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume182K
Avg Volume (10D)—
Shares Outstanding37.6M
MGX News
20 articles- Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing EfficiencyGlobeNewswire Inc.·Apr 16, 2026
- Spotlight On 3 ASX Penny Stocks With Market Caps Under A$2BYahoo Finance·Apr 2, 2026
- Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 5, 2026
- Metagenomi Therapeutics: Q4 Earnings SnapshotYahoo Finance·Mar 5, 2026
- Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial ResultsYahoo Finance·Mar 5, 2026
- Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag EstimatesYahoo Finance·Feb 26, 2026
- Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare ConferenceYahoo Finance·Feb 23, 2026
- Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans?Yahoo Finance·Feb 12, 2026
- Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate OutlookYahoo Finance·Jan 12, 2026
- Trainium3 UltraServers Now Available: Enabling Customers to Train and Deploy AI Models Faster at Lower CostYahoo Finance·Dec 2, 2025
- Amazon Launches New AI Chip While Teasing Future Tech Collaboration With NvidiaYahoo Finance·Dec 2, 2025
- Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature ConferenceYahoo Finance·Dec 1, 2025
- Metagenomi to Present at Jefferies Global Healthcare Conference in LondonYahoo Finance·Nov 17, 2025
- Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer dataBiopharmadive·Nov 12, 2025
- Metagenomi to Advance Hemophilia A Gene Therapy to Clinical TrialsYahoo Finance·Nov 11, 2025
- Metagenomi (MGX) Reports Q3 Loss, Lags Revenue EstimatesYahoo Finance·Nov 11, 2025
- Metagenomi: Q3 Earnings SnapshotYahoo Finance·Nov 11, 2025
- Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership UpdatesYahoo Finance·Nov 11, 2025
- Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical DevelopmentYahoo Finance·Nov 11, 2025
All 20 articles loaded
Price Data
Open$1.43
Previous Close$1.41
Day High$1.44
Day Low$1.38
52 Week High$3.95
52 Week Low$1.25
52-Week Range
$1.25$3.95
$1.43
Fundamentals
Market Cap$53M
P/E Ratio—
EPS$-2.36
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume182K
Avg Volume (10D)—
Shares Outstanding37.6M
About Metagenomi Inc
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company is headquartered in Emeryville, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—